Members Login![]() For a special limited time: Get all 3: currinBiotech.com currinTechnology and rick'sResearch for one low price. Learn more |
Cancer Stem Cells - Max Wicha
publication date: Feb 9, 2013
|
Max Wicha a cancer stem cell pioneer discusses cancer stem cells.
Note that this is quite relevant to our discussion on the ability of Incyte's JAK inhibitors to down regulate interleukin 6 (IL-6) to impact breast cancer stem cells. There is already a clinical trial to investigate ruxolitinib in breast cancer as we discussed recently. He mentions this IL-6 issue at around 8:50. Dr. Wicha is a founder of OncoMed pharmaceuticals a privately held company that has a development alliance agreement with Bayer for WNT pathway drugs. |